47 results about "CD14" patented technology

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention discloses a bifunctional T cell adapter targeting CD14 and CD3 and an application of the bifunctional T cell adapter. Specifically, the invention provides a CD14 and CD3 targeting bifunctional T cell adapter, the CD14 and CD3 targeting bifunctional T cell adapter comprises a skeleton containing an IgG antibody constant region, the skeleton comprises two heavy chains and a light chain, one heavy chain comprises heavy chain constant regions CH1, CH2 and CH3, the other heavy chain comprises CH2 and CH3, the light chain comprises CL, the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer, and the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer. Specifically, the first subunit comprises a light chain variable region of an anti-CD14 antibody and a light chain in the skeleton, the second subunit comprises a heavy chain variable region of the anti-CD14 antibody and a heavy chain in the skeleton, and the third subunit comprises a heavy chain variable region of an anti-CD3 antibody and a light chain variable region. The bifunctional T cell adapter disclosed by the invention has an excellent tumor killing effect.

Provided are: an adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL3, GM-CSF, IL6, APRIL, and BAFF; an AAV vector combination comprising any two or three or more of said AAV vectors; and a method for constructing an acute myeloid leukemia xenograft non-human animal and a method for constructing a multiple myeloma xenograft non-human animal. In addition, further provided is another adeno-associated virus (AAV) vector, the AAV vector comprising a cytokine gene, and the cytokine being selected from any one or two or more of the following: IL2, IL3, IL6, IL15, THPO, SCF, and GM-CSF; further provided is an AAV vector combination comprising any two or three or more of said AAV vectors; and further provided is the use of the AAV vector and AAV vector combination in the construction of a humanized immune system non-human animal, as well as a method for constructing a humanized immune system non-human animal and a method for promoting the differentiation of human hematopoietic stem cells into CD14+ monocytes and CD66b+ granulocytes.

Provided herein are engineered or modified cell lines in which the expression of at least one of ADM2, AURKA, BCL2, CCND1, CHD1, CREB3L3, RIGI / DDX58, ECSIT, EHHADH, ERBB2, FAS, FBXW7, FGFR3, FOXL2, GATA1, HDAC5, HOXA5, HSP90B1, IL6, ITGA2B, KAT5, LAS1L, LIF, NFKB1, NFKB2, NFKB1A, NFE2L2, NGEF, NME1, NR3C1, POLN, PPAR-A, PTEN, RELB, RPA1, RXRA, SMAD4, SS18, TCF7, TGM2, THEM6, TNFAIP3, TP63, TRPC1, DBH, ITGAM, HHEX, TXNIP, ASNS, PLEKH02, CDKN1A, C5orf64, COL20A1, GJB3, ISYNA1, PARD6G-AS1, ACTA1, ACTC1, ADCY10, ADCY4, ADORA2A, ALKBH5, ATP1A4, ATP1B2, ATP2B2, BAIAP3, BAZ1B, BTK, CBL, CCNA1, CD14, CLTC, COPS3, CRHR2, CXADR, DAPK1, DCTN5, DYNLRB1, EME2, EXOC3L1, EYA3, EYA4, FANCA, FEN1, GAK, GCGR, GHSR, GSK3B, H2BC5, H4C7, H4C8, HAP1, HCAR1, INO80, KCNB1, LAT2, LIN7C, MAP1B, MBD4, MYH11, MYH15, MYH3, MYH7B, NAPA, NKD2, NLRP5, NPM2, NR4A3, NFRKB, PAXIP1, PIAS1, PIAS4, POLE, POLE3, POLD1, POLH, PPP4R2, PTGER3, RAB25, RAB40C, RAB44, RAD9A, REV1, RIF1, RNF111, RNF168, RNF4, RPA4, RTEL1, SCRIB, SNRNP70, SPHK1, STX3, SYT1, SYT2, SYT5, SYTL1, SYNJ2, TERF2, TNFSF10, TNPO2, TOP3A, TRIM25, TRIM72, TXLNA, UBA7, UNC5A, VAV3, VPS18, WASL, XRN2, and YY1 is altered as compared to a control cell line. Also provided are methods of producing recombinant AAV particles in said engineered or modified cell lines.

The invention relates to the technical field of biological medicine, in particular to application of S100A9 protein to preparation of a product for predicting the recurrence risk of AML. The product is used for detecting a marker CD15, a marker CD33, a marker CD14, a marker CD15, a marker CD33, a marker CD64, a marker CD5, a marker CD14, a marker CD10, a marker CD19, a marker CD33, a marker CD34, a marker CD64, a marker CD117, a marker CD13 or a marker CD45. Therefore, the accuracy of predicting the AML recurrence risk is improved.

This invention discloses a bifunctional T-cell connector targeting CD14 and CD3 and its application. Specifically, this invention provides a bifunctional T-cell connector targeting CD14 and CD3, comprising a backbone containing a constant region of an IgG antibody. The backbone includes two heavy chains and one light chain, wherein one heavy chain includes a heavy chain constant region CH1, CH2, and CH3, and the other heavy chain includes CH2 and CH3. The light chain includes CL. The bifunctional T-cell connector targeting CD14 and CD3 is a heterotrimer, specifically: a first subunit includes a variable region of the light chain of an anti-CD14 antibody and the light chain in the backbone; a second subunit includes a variable region of the heavy chain of an anti-CD14 antibody and one heavy chain in the backbone; and a third subunit includes a variable region of the heavy chain of an anti-CD3 antibody and a variable region of the light chain. The bifunctional T-cell connector of this invention exhibits excellent tumor-killing effects.

The invention discloses a method for detecting aortic dissection through peripheral blood BRD4 based on flow cytometry and application. The invention belongs to the technical field of biology, and particularly relates to a method for detecting aortic dissection through peripheral blood BRD4 based on flow cytometry and application. The method for detecting the content or expression level of the bromodomain-containing protein 4 in the sample to be detected comprises the following steps: 1) treating the sample to be detected to obtain mononuclear cells; the method comprises the following steps of (1) determining a mononuclear cell, (2) determining a fluorescein coupling antibody composition of a detection index according to a flow cytometry color matching scheme, (3) uniformly mixing the mononuclear cell in the step (1) and the fluorescein coupling antibody in the step (2), incubating in a dark place and dyeing, (4) loading and testing a sample by a spectrum flow cytometry, and (5) analyzing a data result, and the detection indexes in the step (2) are CD45, CD11B, CD66B, CD14, CC16 and BRD4.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The present disclosure provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject. The present disclosure specifically provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject, the composition containing macrophages derived from monocytes stimulated with IL-34. The composition can be produced by a method comprising: a step for preparing a sample comprising CD14-positive cells; an optional step for isolating the CD14-positive cells from the sample if required; and a step for bringing the sample or the isolated CD14-positive cells into contact with IL-34.

The invention provides an antibody composition for detecting immature mononuclear cells and application thereof, the antibody composition for detecting the immature mononuclear cells comprises a first group of antibodies and a second group of antibodies, the first group of antibodies comprises a CD15 antibody, a CD117 antibody, a CD34 antibody, a CD33 antibody, a CD14 antibody, an HLA-DR antibody, a CD13 antibody, a CD38 antibody, a CD64 antibody, a CD19 antibody, a CD56 antibody, a CD7 antibody and a CD45 antibody; and the second group of antibodies comprise an HLA-DR antibody, a CD64 antibody, a CD33 antibody, a CD14 antibody, a CD65 antibody and a CD45 antibody. According to the present invention, the flow cytometry is adopted to detect, and the antibody composition of the first group of antibodies and the second group of antibodies is provided, such that the detection sensitivity and the specificity are improved.

The application relates to the technical field of medical detection, in particular to a kit, a method and a system for predicting bacterial infection. The application provides a kit for predicting bacterial infection, which comprises an antibody combination for specifically recognizing CD64, CD14 and CD14, and the antibodies are respectively labeled with mutually distinguishable fluorescent dyes. Meanwhile, the application provides a method for predicting bacterial infection, which comprises obtaining the counts of neutrophils, lymphocytes and monocytes in a to-be-detected sample, and the fluorescent intensities of CD64 and CD14 on the cell subgroups, and calculating four characteristic parameters IDXNLR, IDXLMR, IDXCD64 and IDXCD14; and then inputting the parameters into a pre-trained infection diagnosis model to output a risk score for judging the infection state (especially bacterial infection). The model significantly improves the accuracy and specificity of distinguishing bacterial infection from non-bacterial infection (such as viral infection or healthy state) by comprehensively integrating immune parameters in multiple dimensions.

The present disclosure relates to methods of manufacturing Chimeric Antigen Receptor (CAR) T cells. Notably, the manufacturing method omits the CD14+ / CD25+ depletion step. Additionally, by starting with CD62L enrichment of naïve and memory T cells, the resulting CAT T cells show reduced release of proinflammatory cytokines. Furthermore, the transduced cells show improved quiescence after removal of the transactivation agent.

The invention belongs to the technical field of medicines, discloses application of a compound aureomycin A for preventing and treating leukemia by inducing differentiation of leukemia HL-60, and particularly discloses application of the compound aureomycin A shown in a formula (I) in inducing expression of mature macrophage markers CD11b, CD14 and CSF1R of leukemia HL-60 cells to induce cell differentiation for preventing and treating leukemia. Pharmacological experiments prove that the aureomycin A can be used for remarkably inducing the expression of CD11b, CD14 and CSF1R in leukemia HL-60 cells. Experimental results show that the aureomycin A has the effect of inducing leukemia cell differentiation to prevent and treat leukemia.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The invention relates to the technical field of antibodies, in particular to an anti-mouse CD14 antibody and application thereof. The anti-mouse CD14 antibody comprises a heavy chain variable region and a light chain variable region, amino acid sequences of CDR1-3 of the heavy chain variable region are sequentially shown as SEQ ID NO.1-3, amino acid sequences of CDR1 and CD3 of the light chain variable region are shown as SEQ ID NO.4 and SEQ ID NO.5, and an amino acid sequence of CDR2 is RAS. The anti-mouse CD14 antibody provided by the invention can be specifically combined with mouse CD14, has relatively high affinity to the mouse CD14, and can be used for detecting the mouse CD14 or detecting or sorting CD14 + cells; when being used for cell sorting, the material has high enrichment degree on CD14 + cells, the purity of the sorted cells is high, and the material has a better application prospect in CD14 detection or CD14 + cell preparation.

The invention relates to a diagnostic microarray device comprising: a substrate, preferably formed of a glass material; wherein a plurality of probes attached or otherwise associated with the substrate, each probe being specific to one allele of a single nucleotide polymorphism (SNP), said SNR being selected from the group consisting of IL1B+3877, IL1B-511, and IL6-1363, and preferably IL10-592, CD14-260 and COX2+8473.

The invention provides a marker for prognosis of anti-MDA5 antibody positive dermatomyositis related interstitial pneumonia and application thereof, the marker is the proportion of CX3CR1 + CD14 + mononuclear cells in PBMC, and the marker is helpful for early recognition of high-risk patients, convenient for timely adjustment of therapeutic schedules and prevention of disease deterioration. The method for detecting the proportion of the CX3CR1 + CD14 + monocytes in the PBMC is mature and rapid, and can be used for multiple times of detection in different stages of diseases and dynamically monitoring the change of the illness state. The detection result of the proportion of the CX3CR1 + CD14 + monocytes in the PBMC is presented in a numerical form, the objectivity is high, the method is not influenced by the experience of an operator, and compared with subjective judgment of clinical symptoms and signs, the proportion of the CX3CR1 + CD14 + monocytes in the PBMC can be used as a prognostic marker to quantitatively evaluate the severity and treatment response of diseases, and an objective basis is provided for clinical decision making.

The present disclosure relates to CD14 + The present invention provides rAAV vectors and rAAV virions that specifically express exogenous nucleic acid sequences in cells. The rAAV vectors or virions are useful for specifically expressing exogenous nucleic acid sequences encoding, for example, cancer antigens, viral antigens, and / or bacterial antigens in monocytes and dendritic cells. rAAV-transduced CD14 + The cells can be used as antigen-presenting cells to induce antigen-specific T cell responses. The present disclosure further provides methods for producing rAAV virions and methods of immunotherapy.

This invention discloses a panel for detecting histiocytic / dendritic cell tumors based on 10-color multiparameter flow cytometry and its applications. The panel is composed of the following antibodies: CD4, HLA-DR, CD45, CD1c, CD207, CD123, CD56, CD1a, CD3, and CD14. The flow cytometry protocol provided by this invention enables rapid, objective, and quantitative analysis of large numbers of cells, and is particularly suitable for detecting small tumor populations in mixed cell populations or assessing the heterogeneity of antigen expression. This is an important supplement to existing pathological diagnostic systems and provides key evidence for precision medicine.

This invention discloses an analytical method for detecting the H3K27me3 level of various immune cell populations in human whole blood using flow cytometry. The method involves a one-step pretreatment process of lysing erythrocytes and simultaneously fixing leukocytes in a human whole blood sample. Fluorescently labeled antibodies (BV785-CD3, BV650-CD19, BV605-CD14, AF488-HLA-DR, AF647-H3K27, Pacific Blue-H3) are used to stain the lysed and fixed leukocytes. After antibody staining, the sample is subjected to flow cytometry for gating analysis. The H3K27me3 / H3 level in each immune cell population—T cells (CD3+CD19-), B cells (CD3-CD19+), monocytes (CD14+HLADR+), and granulocytes (CD14-HLADR-)—is calculated using a formula. The whole blood sample, after the one-step lysing and fixing process, can be stored at -60 to -90°C for 5 days. The method exhibits good accuracy, reliability, and stability.

The application belongs to the field of biological medicine, and particularly relates to a homogeneous chemiluminescence kit for detecting platelet-monocyte aggregates and a detection method thereof. The kit comprises: R1 reagent: CD41 antibody-DNA1 conjugate; R2 reagent: CD14 antibody-DNA2 conjugate; R3 reagent: DNA3 labeled with acridinium ester; and R4 reagent: antioxidant combined with graphene oxide. The application realizes direct whole blood detection of platelet-monocyte aggregates in 5-10 minutes through homogeneous chemiluminescence+orthogonal DNA hybridization+special sample stabilizer, greatly simplifies the process, reduces the cost, and enables the sample to be stable at room temperature for 6 hours. The detection result is highly correlated with flow cytometry, and has good diagnostic efficiency for sepsis.

The application belongs to the field of biological medicine, and particularly relates to a homogeneous chemiluminescence kit for detecting platelet-monocyte aggregates and a detection method thereof. The kit comprises: R1 reagent: CD41 antibody-DNA1 conjugate; R2 reagent: CD14 antibody-DNA2 conjugate; R3 reagent: DNA3 labeled with acridinium ester; and R4 reagent: antioxidant combined with graphene oxide. The application realizes direct whole blood detection of platelet-monocyte aggregates in 5-10 minutes through homogeneous chemiluminescence+orthogonal DNA hybridization+special sample stabilizer, greatly simplifies the process, reduces the cost, and enables the sample to be stable at room temperature for 6 hours. The detection result is highly correlated with flow cytometry, and has good diagnostic efficiency for sepsis.

The invention discloses a method for detecting peripheral blood immune cells through multi-parameter flow cytometry. The core of the method is that an optimized eight-color antibody combination is adopted and comprises CD45, CD3, CD19, CD16, CD56, CD4, CD8 and CD14, and a specific fluorescein pairing scheme is specified. According to the method, the detection stability is ensured through standardized sample dyeing and cracking washing processes in combination with precision calibration of a flow cytometer. In the data analysis stage, a set of serialization gate setting strategy is innovatively adopted, and fragments, adhesions and monocytes are sequentially eliminated, so that T cells (CD4 + and CD8 +) and B cells are accurately distinguished in a purified lymphocyte population, and NK cells are further subdivided into three functional subgroups, namely CD16 + CD56-, CD16 + CD56dim and CD16-CD56light. The method solves the problems of rough typing, poor accuracy and low repeatability in the prior art, and realizes efficient, accurate and repeatable detection of peripheral blood immune cells.

This disclosure relates generally to methods and agents for treating acute neuroinflammatory injury, such as stroke (e.g. ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage. In particular, the present disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injury.

The invention provides an antibody composition for detecting AML (acute myeloid leukemia) accompanied with CBF beta MYH11. The antibody composition comprises CD2, CD34, CD117, CD64, CD14, CD33, HLA-DR (human leukocyte antigen-DR), CD15, CD11b, CD13, CD38 and CD45 antibodies. During detection, the antibody composition is divided into two types of antibody combinations according to detection targets, and then samples are respectively added for flow cytometry detection; when the proportion of original myeloid cells / nucleated cells is between 6% and 78%, the proportion of mononuclear cells / nucleated cells is greater than 22%, and the proportion of CD2 / mononuclear cells is greater than 20%, determining that the sample is AML with CBF beta MYH11. The method provided by the invention is simple and low in cost, can be used for judging whether the AML patient has CBF beta MYH11 positive or not without further molecular biological PCR (Polymerase Chain Reaction) screening, and has a great practical value.

This invention provides a biomarker for predicting the prognosis of anti-MDA5 antibody-positive dermatomyositis-associated interstitial pneumonia and its application. The biomarker is CX3CR1 in PBMCs. + CD14 + The proportion of monocytes helps in the early identification of high-risk patients, facilitating timely adjustments to treatment plans and preventing disease progression. CX3CR1 in PBMCs... + CD14 + The method for detecting monocyte proportion is mature and rapid, allowing for multiple tests at different stages of the disease to dynamically monitor disease changes. CX3CR1 in PBMCs... + CD14 + The results of monocyte proportion detection are presented in numerical form, which is highly objective and unaffected by the operator's experience. Compared with subjective judgment based on clinical symptoms and signs, CX3CR1 in PBMCs... + CD14 + The proportion of monocytes, as a prognostic marker, can quantitatively assess disease severity and treatment response, providing an objective basis for clinical decision-making.

The invention discloses a mesenchymal stem cell culture medium containing traditional Chinese medicine components and a preparation method and application thereof. The mesenchymal stem cell culture medium is a culture system composed of a basic culture medium and additives. DMEM / F12 is used as a basic culture medium, an additive solution comprises fetal calf serum, an American ginseng extract and a ganoderma spore extract, and the cell anti-inflammatory capacity, the repair promoting capacity and the angiogenesis promoting capacity are improved. The mesenchymal stem cell culture medium containing the traditional Chinese medicine components can be used for culturing mesenchymal stem cells, and after cells are inoculated for 24 hours, the original culture medium is abandoned, and the culture medium is replaced. By using the culture medium and the use method, the positive rate of the obtained mesenchymal stem cells CD73, CD90 and CD105 is greater than 95%, the positive rate of the obtained mesenchymal stem cells CD44, CD45, CD19, CD34, CD14 and HLA-DR is less than 2%, and the amplification efficiency is improved. Higher anti-inflammatory, repair-promoting and angiogenesis-promoting capacities are realized.

The application discloses a method for detecting aortic dissection based on peripheral blood BRD4 by using flow cytometry and application thereof. The application belongs to the technical field of biology and particularly relates to a method for detecting aortic dissection based on peripheral blood BRD4 by using flow cytometry and application thereof. The method for detecting the content or expression level of bromodomain-containing protein 4 in a to-be-detected sample established by the application comprises the following steps: 1) processing a to-be-detected sample to obtain single nucleus cells; 2) determining a fluorescein-coupled antibody composition of a detection index according to a flow cytometry color matching scheme; 3) mixing the single nucleus cells in step 1) and the fluorescein-coupled antibody in step 2) uniformly, and performing staining by incubation in the dark; 4) performing sample testing on a spectrum flow cytometer; and 5) performing data result analysis. The detection index in step 2) is CD45, CD11B, CD66B, CD14, CC16 and BRD4.

Provided is an anti-human CD14 antibody, comprising a heavy chain and a light chain. An amino acid sequence of a heavy chain variable region comprises a sequence as shown in SEQ ID NO: 2, and an amino acid sequence of a light chain variable region comprises a sequence as shown in SEQ ID NO: 4. The coupling of the anti-human CD14 antibody and magnetic beads enables the simple and rapid sorting of high-purity CD14+ monocytes from fresh or cryopreserved peripheral blood mononuclear cells, with good specificity.

The application discloses application of an antibody in preparation of a drug for treating HUS caused by Shiga toxin type II. Application of an antibody for mononuclear cells in preparation of a drug for treating hemolytic uremic syndrome. The antibody for mononuclear cells is a CD14 antibody. Through single cell sequencing technology, the application finds positive cells combined with Stx2 in peripheral blood, further bioinformatics analysis obtains that most of the cells combined with Stx2 are mononuclear cells, and then the CD14 antibody for mononuclear cells is used to treat HUS caused by Stx2, and the result shows that the CD14 antibody has good treatment effect. Therefore, the antibody for mononuclear cells, especially the CD14 antibody, can be applied in preparation of a drug for treating HUS caused by Stx2.